Growth Metrics

Exagen (XGN) Liabilities and Shareholders Equity (2018 - 2026)

Exagen filings provide 9 years of Liabilities and Shareholders Equity readings, the most recent being $52.0 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 28.94% to $52.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $231.6 million, a 30.17% increase, with the full-year FY2025 number at $58.0 million, up 29.84% from a year prior.
  • Liabilities and Shareholders Equity hit $52.0 million in Q1 2026 for Exagen, down from $58.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $122.0 million in Q1 2022 to a low of $40.3 million in Q1 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $58.8 million (2025), compared with a mean of $67.0 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: crashed 40.03% in 2023 and later soared 44.07% in 2025.
  • Exagen's Liabilities and Shareholders Equity stood at $86.2 million in 2022, then tumbled by 33.96% to $56.9 million in 2023, then fell by 21.52% to $44.7 million in 2024, then grew by 29.84% to $58.0 million in 2025, then fell by 10.45% to $52.0 million in 2026.
  • The last three reported values for Liabilities and Shareholders Equity were $52.0 million (Q1 2026), $58.0 million (Q4 2025), and $62.8 million (Q3 2025) per Business Quant data.